26
https://pubmed.ncbi.nlm.nih.gov/38114088
The study found that higher neutralizing and S1-specific IgG antibodies in immunocompromised COVID-19 patients were associated with a faster decline in viable virus shedding, suggesting the potential benefits of enhancing their humoral immune response through vaccination or monoclonal antibody treatments.